Rapidly progressive dementias and the treatment of human prion diseases

Bibliography

• Geschwind MD, Haman A, Miller BL. Rapidly progressive dementia. Neurol Clin 2007;25:783-807
   PubMed Web of Science ®Google Scholar
• Geschwind MD, Shu H, Haman A, Rapidly progressive dementia. Ann Neurol 2008;64:97-108
   PubMed Web of Science ®Google Scholar
• Woodruff BK. Evaluation of rapidly progressive dementia. Semin Neurol 2007;27:363-75
   PubMedGoogle Scholar
• Josephs KA, Ahlskog JE, Parisi JE, Rapidly progressive neurodegenerative dementias. Arch Neurol 2009;66:201-7
   PubMedGoogle Scholar
• Kelley BJ, Boeve BF, Josephs KA. Rapidly progressive young-onset dementia. Cogn Behav Neurol 2009;22:22-7
   PubMedGoogle Scholar
• Papageorgiou SG, Kontaxis T, Bonakis A, Rapidly progressive dementia: causes found in a greek tertiary referral center in Athens. Alzheimer Dis Assoc Disord 2009;23:337-46
   PubMed Web of Science ®Google Scholar
• Griffith JS. Self-replication and scrapie. Nature 1967;215:1043-4
   PubMed Web of Science ®Google Scholar
• Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982;216:136-44
   PubMed Web of Science ®Google Scholar
• Soto C, Estrada L, Castilla J. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends in Biochem Sci 2006;31:150-5
   PubMed Web of Science ®Google Scholar
• Kim J, Cali I, Surewicz K, Mammalian prions generated from bacterially expressed prion protein in the absence of any mammalian cofactors. J Biol Chem 2010;285:14083-7
   PubMed Web of Science ®Google Scholar
• Wang F, Wang X, Yuan C, Ma J. Generating a prion with bacterially expressed recombinant prion protein. Science 2010;327:1132-5
   PubMed Web of Science ®Google Scholar
• Bueler H, Aguzzi A, Sailer A, Mice devoid of PrP are resistant to scrapie. Cell 1993;73:1339-47
   PubMed Web of Science ®Google Scholar
• Alper T, Cramp WA, Haig DA, Clarke MC. Does the agent of scrapie replicate without nucleic acid? Nature 1967;214:764-6
   PubMed Web of Science ®Google Scholar
• McKinley MP, Bolton DC, Prusiner SB. A protease-resistant protein is a structural component of the Scrapie prion. Cell 1983;35:57-62
   PubMed Web of Science ®Google Scholar
• Johnson RT, Gibbs CJ. Creutzfeldt–Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med 1998;339:1994-2004
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Sigurdson C, Heikenwaelder M. Molecular mechanisms of prion pathogenesis. Annu Rev Pathol 2008;3:11-40
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO manual for surveilance of human transmissible spongiform encephalopathies including variant Creutzfeldt–Jakob disease. 2003
   Google Scholar
• Appleby BS, Appleby KK, Crain BJ, Characteristics of established and proposed sporadic Creutzfeldt–Jakob disease variants. Arch Neurol 2009;66:208-15
   PubMed Web of Science ®Google Scholar
• Appleby B, Appleby K, Rabins P. Does the presentation of Creutzfeldt–Jakob disease vary by age or presumed etiology? A meta-analysis of the past 10 years. J Neuropsychiatry Clin Neurosci 2007;19:428-35
   PubMed Web of Science ®Google Scholar
• Wieser HG, Schindler K, Zumsteg D. EEG in Creutzfeldt–Jakob disease. Clin Neurophysiol 2006;117:935-51
   PubMed Web of Science ®Google Scholar
• Geschwind MD, Martindale J, Miller D, Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt–Jakob disease. Arch Neurol 2003;60:813-16
   PubMedGoogle Scholar
• Zerr I, Kallenberg K, Summers DM, Updated clinical diagnostic criteria for sporadic Creutzfeldt Jakob disease. Brain 2009;132:2659-68
   PubMed Web of Science ®Google Scholar
• David A, Grant R, Ballantyne J. Unsuccessful treatment of Creutzfeldt–Jakob disease with acyclovir. Lancet 1984;323:512-13
   Google Scholar
• Newman PK. Acyclovir in Creutzfeldt–Jakob disease. Lancet 1984;323:793
   Google Scholar
• Kovanen J, Haltia M, Cantell K. Failure of interferon to modify Creutzfeldt–Jakob disease. Br Med J 1980;280:902
   PubMedGoogle Scholar
• Furlow T, Whitley R, Wilmes F. Repated suppression of Creutzfeldt–Jakob disease with vidarabine. Lancet 1982;320:564-5
   Google Scholar
• Terzano MG, Montanari E, Calzetti S, The effect of amantadine on arousal and EEG patterns in Creutzfeldt–Jakob disease. Arch Neurol 1983;40:555-9
   PubMedGoogle Scholar
• Neri G, Figa-Talamanca L, Di Battista GC, Lo Russo F. [Amantadine in Creutzfeldt–Jakob disease. Review of the literature and case contribution]. Riv Neurobiol 1984;30:47-56
   PubMedGoogle Scholar
• Ratcliffe J, Rittman A, Wolf S, Verity MA. Creutzfeldt–Jakob disease with focal onset unsuccessfully treated with amantadine. Bull Los Angeles Neurol Soc 1975;40:18-20
   PubMedGoogle Scholar
• Braham J. Jakob-Creutzfeldt disease: treatment by amantadine. Br Med J 1971;4:212-13
   PubMedGoogle Scholar
• Sanders WL, Dunn TL. Creutzfeldt–Jakob disease treated with amantidine. A report of two cases. J Neurol Neurosurg Psychiatry 1973;36:581-4
   PubMed Web of Science ®Google Scholar
• Sanders WL. Short report: Creutzfeldt–Jakob disease treated with amantadine. J Neurol Neurosurg Psychiatry 1979;42:960-1
   PubMed Web of Science ®Google Scholar
• Villa G, Caltagirone C, Macchi G. Unusual clinical course in a case of Creutzfeldt–Jakob disease. Ital J Neurol Sci 1982;3:155-8
   PubMedGoogle Scholar
• Pocchiari M, Schmittinger S, Masullo C. Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters. J Gen Virol 1987;68:219-23
   PubMed Web of Science ®Google Scholar
• Masullo C, Macchi G, Xi YG, Pocchiari M. Failure to ameliorate Creutzfeldt–Jakob disease with amphotericin B therapy. J Infect Dis 1992;165:784-5
   PubMed Web of Science ®Google Scholar
• Floel A, Reilmann R, Frese A, Ludemann P. Anticonvulsants for Creutzfeldt–Jakob disease? Lancet 2003;361:224
   PubMedGoogle Scholar
• Arruda WO, Bordignon KC, Milano JB, Ramina R. [Creutzfeldt–Jakob disease, Heidenhain variant: case report with MRI (DWI) findings]. Arq Neuropsiquiatr 2004;62:347-52
   PubMedGoogle Scholar
• Imperiale D, Bortolotto S, Cucatto A, Levetiracetam control of myoclonus in a patient with Creutzfeldt–Jakob disease. Eur Neurol 2003;49:189-90
   PubMedGoogle Scholar
• Belcastro V, Mattucci E, Rossi A, Vomiting due to intravenous levetiracetam in a case of Creutzfeldt–Jakob disease. Epilepsy Behav 2010;17:133
   PubMedGoogle Scholar
• Drisko JA. The use of antioxidants in transmissible spongiform encephalopathies: a case report. J Am Coll Nutr 2002;21:22-5
   PubMed Web of Science ®Google Scholar
• Perovic S, Schroder HC, Pergande G, Effect of flupirtine on bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126). Exp Neurol 1997;147:518-24
   PubMed Web of Science ®Google Scholar
• Otto M, Cepek L, Ratzka P, Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 2004;62:714-18
   PubMed Web of Science ®Google Scholar
• Pocchiari M, Puopolo M, Croes EA, Predictors of survival in sporadic Creutzfeldt–Jakob disease and other human transmissible spongiform encephalopathies. Brain 2004;127:2348-59
   PubMed Web of Science ®Google Scholar
• Riemer C, Gultner S, Heise I, Neuroinflammation in prion diseases: concepts and targets for therapeutic intervention. CNS Neurol Disord Drug Targets 2009;8:329-41
   PubMedGoogle Scholar
• Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci 2001;98:9836-41
   PubMed Web of Science ®Google Scholar
• Scoazec J, Krolak-Salmon P, Casez O, Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt–Jakob disease. Ann Neurol 2003;53:546-7
   PubMed Web of Science ®Google Scholar
• Nakajima M, Yamada T, Kusuhara T, Results of quinacrine administration to patients with Creutzfeldt–Jakob disease. Dement Geriatr Cogn Disord 2004;17:158-63
   PubMed Web of Science ®Google Scholar
• Satoh K, Shirabe S, Eguchi K, Toxicity of quinacrine can be reduced by co-administration of P-glycoprotein inhibitor in sporadic Creutzfeldt–Jakob disease. Cell Mol Neurobiol 2004;24:873-5
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Hirata K, Tanaka H, Yamada T. [Quinacrine administration to a patient with Creutzfeldt–Jakob disease who received a cadaveric dura mater graft – an EEG evaluation]. Rinsho Shinkeigaku 2003;43:403-8
   PubMedGoogle Scholar
• Martinez-Lage JF, Rabano A, Bermejo J, Creutzfeldt–Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine. Surg Neurol 2005;64:542-5
   PubMed Web of Science ®Google Scholar
• Benito-Leon J. Combined quinacrine and chlorpromazine therapy in fatal familial insomnia. Clin Neuropharmacol 2004;27:201-3
   PubMed Web of Science ®Google Scholar
• Bertrand A, Martinez-Almoyna L, De Broucker T. [Hereditary Creutzfeldt–Jakob disease caused by a mutation at codon 200]. Rev Neurol 2005;161:351-4
   PubMedGoogle Scholar
• Collinge J, Gorham M, Hudson F, Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 2009;8:334-44
   PubMed Web of Science ®Google Scholar
• Haik S, Brandel JP, Salomon D, Compassionate use of quinacrine in Creutzfeldt–Jakob disease fails to show significant effects. Neurology 2004;63:2413-15
   PubMed Web of Science ®Google Scholar
• Geschwind M, Kuo A, Raudabaugh B, A randomized, double-blind, controlled study of the efficacy of quinacrine in the treatment of sporadic CJD. Poster presentation at Thessaloniki-Chalkidiki: Prion 2009
   Google Scholar
• CJD (Creutzfeldt–Jakob Disease) Quinacrine Study. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available from: www.clinicaltrials.gov/ct2/show/NCT00183092?term=quinacrine&rank=2 [Last accessed 4 August 2010]
   Google Scholar
• Appleby BS. Psychotropic medications and the treatment of human prion diseases. CNS Neurol Disord Drug Targets 2009;8:353-62
   PubMed Web of Science ®Google Scholar
• Dervaux A, Vicart S, Lopes F, Le Borgne MH. [Psychiatric manifestations of a new variant of Creutzfeldt–Jakob disease. Apropos of a case]. Encephale 2001;27:194-7
   PubMedGoogle Scholar
• Clarke CE, Bamford JM, House A. Dyskinesia in Creutzfeldt–Jakob disease precipitated by antidepressant therapy. Mov Disord 1992;7:86-7
   PubMedGoogle Scholar
• Ehlers B, Diringer H. Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J Gen Virol 1984;65:1325-30
   PubMed Web of Science ®Google Scholar
• Doh-ura K, Ishikawa K, Murakami-Kubo I, Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 2004;78:4999-5006
   PubMed Web of Science ®Google Scholar
• Dyer O. Family finds hospital willing to give experimental CJD treatment. BMJ 2003;326:8
   PubMedGoogle Scholar
• Gould M. Medicines committee felt unable to recommend use of pentosan polyphosphate in vCJD. BMJ 2003;327:770
   PubMedGoogle Scholar
• Mayor S. Small improvement seen in teenager with vCJD. BMJ 2003;327:765
   Google Scholar
• Todd N, Morrow J, Doh-ura K, Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt–Jakob disease. J Infect 2005;50:394-6
   PubMed Web of Science ®Google Scholar
• Whittle IR, Knight RSG, Will RG. Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt–Jakob disease. Acta Neurochir 2006;148:677-9
   PubMed Web of Science ®Google Scholar
• Parry A, Baker I, Stacey R, Wimalaratna S. Long term survival in a patient with variant Creutzfeldt–Jakob disease treated with intraventricular pentosan polysulphate. J Neurol Neurosurg Psychiatry 2007;78:733-4
   PubMed Web of Science ®Google Scholar
• Terada T, Tsuboi Y, Obi T, Less protease-resistant PrP in a patient with sporadic CJD treated with intraventricular pentosan polysulphate. Acta Neurol Scand 2010;121:127-30
   PubMed Web of Science ®Google Scholar
• Rainov NG, Tsuboi Y, Krolak-Salmon P, Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? Expert Opin Biol Ther 2007;7:713-26
   PubMed Web of Science ®Google Scholar
• Bone I, Belton L, Walker AS, Darbyshire J. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol 2008;15:458-64
   PubMed Web of Science ®Google Scholar
• Tsuboi Y, Doh-ura K, Yamada T. Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases. Neuropathology 2009;29:632-6
   PubMed Web of Science ®Google Scholar
• Forloni G, Salmona M, Marcon G, Tagliavini F. Tetracyclines and prion infectivity. Infect Disord Drug Targets 2009;9:23-30
   PubMedGoogle Scholar
• Zerr I. Therapeutic trials in human transmissible spongiform encephalopathies: recent advances and problems to address. Infect Disord Drug Targets 2009;9:92-9
   PubMedGoogle Scholar
• De Luigi A, Colombo L, Diomede L, The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS ONE 2008;3:e1888
   PubMed Web of Science ®Google Scholar
• Zerr I. Clinical diagnosis of CJD: are there predictors of treatment response? Oral presentation at Thessaloniki-Chalkidiki: Prion 2009
   Google Scholar
• Brandel J, Haik S. Doxycycline versus placebo trial in human prion diseases: a therapeutic challenge. Rev Neurol 2010;166:266-8
   PubMedGoogle Scholar
• Sakaguchi S. Prospects for preventative vaccines against prion diseases. Protein Pept Lett 2009;16:260-70
   PubMedGoogle Scholar
• White MD, Mallucci GR. RNAi for the treatment of prion disease: a window for intervention in neurodegeneration? CNS Neurol Disord Drug Targets 2009;8:342-52
   PubMedGoogle Scholar
• Mallucci G, Dickinson A, Linehan J, Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 2003;302:871-4
   PubMed Web of Science ®Google Scholar
• Mallucci GR, White MD, Farmer M, Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 2007;53:325-35
   PubMed Web of Science ®Google Scholar
• Linden R, Martins VR, Prado MAM, Physiology of the prion protein. Physiol Rev 2008;88:673-728
   PubMed Web of Science ®Google Scholar
• Collinge J, Whittington MA, Sidle KC, Prion protein is necessary for normal synaptic function. Nature 1994;370:295-7
   PubMed Web of Science ®Google Scholar
• Cortelli P, Perani D, Montagna P, Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies. Brain 2006;129:668-75
   PubMed Web of Science ®Google Scholar
• Appleby BS, Appleby KK, Onyike CU, Wallin MT. Initial diagnosis predicts survival time in human prion disease. Poster presentation at Madrid: Prion 2008
   Google Scholar
• Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain 2006;129:2241-65
   PubMed Web of Science ®Google Scholar
• Stewart L, Rydzewska L, Keogh G, Knight R. Systematic review of therapeutic interventions in human prion disease. Neurology 2008;70:1272-81
   PubMed Web of Science ®Google Scholar
• Brown P. An historical perspective on efforts to treat transmissible spongiform encephalopathy. CNS Neurol Disord Drug Targets 2009;8:316-22
   PubMedGoogle Scholar
• Pocchiari M, Ladogana A, Graziano S, Puopolo M. Creutzfeldt–Jakob disease: hopes for therapy. Eur J Neurol 2008;15:435-6
   PubMedGoogle Scholar
• Parchi P, Giese A, Capellari S, Classification of sporadic Creutzfeldt–Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999;46:224-33
   PubMed Web of Science ®Google Scholar
• Pocchiari M. Pentosan polysulphate: a friendly delivery system for therapy in prion diseases. Washington, DC: CJD Oral presentation at the Foundation Family Conference and CJD 2009
   Google Scholar